• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Sorafenib-Related Hand-Foot Skin Reaction Improves, Not Worsens, with Continued Treatment.

作者信息

Flaherty Keith T, Brose Marcia S

机构信息

Abramson Cancer Center of the University of Pennsylvania Philadelphia, Pennsylvania.

出版信息

Clin Cancer Res. 2009 Dec 15;15(24):7749. doi: 10.1158/1078-0432.CCR-09-1190.

DOI:10.1158/1078-0432.CCR-09-1190
PMID:20008857
Abstract
摘要

相似文献

1
Sorafenib-Related Hand-Foot Skin Reaction Improves, Not Worsens, with Continued Treatment.
Clin Cancer Res. 2009 Dec 15;15(24):7749. doi: 10.1158/1078-0432.CCR-09-1190.
2
Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy.索拉非尼治疗患者的手足皮肤反应：多靶点激酶抑制剂治疗所致皮肤表现的临床病理研究
Br J Dermatol. 2008 Mar;158(3):592-6. doi: 10.1111/j.1365-2133.2007.08357.x. Epub 2007 Dec 6.
3
Successful topical treatment of sorafenib-induced hand-foot skin reaction in a child with hepatocellular carcinoma.成功局部治疗一名患有肝细胞癌儿童的索拉非尼诱导的手足皮肤反应。
Pediatr Dermatol. 2009 May-Jun;26(3):349-50. doi: 10.1111/j.1525-1470.2009.00933.x.
4
Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor.新型多激酶抑制剂索拉非尼皮肤不良反应的前瞻性研究。
Arch Dermatol. 2008 Jul;144(7):886-92. doi: 10.1001/archderm.144.7.886.
5
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.索拉非尼用于转移性肾细胞癌患者的II期安慰剂对照随机停药试验。
J Clin Oncol. 2006 Jun 1;24(16):2505-12. doi: 10.1200/JCO.2005.03.6723. Epub 2006 Apr 24.
6
Sorafenib for the treatment of advanced renal cell carcinoma.索拉非尼用于治疗晚期肾细胞癌。
Clin Cancer Res. 2006 Dec 15;12(24):7271-8. doi: 10.1158/1078-0432.CCR-06-1249.
7
Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.索拉非尼的安全性、药代动力学及初步抗肿瘤活性：对四项晚期难治性实体瘤患者I期试验的综述
Oncologist. 2007 Apr;12(4):426-37. doi: 10.1634/theoncologist.12-4-426.
8
Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.索拉非尼单药治疗复发或难治性晚期非小细胞肺癌的多中心、非对照II期试验。
J Clin Oncol. 2009 Sep 10;27(26):4274-80. doi: 10.1200/JCO.2009.22.0541. Epub 2009 Aug 3.
9
Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America.北美晚期肾细胞癌索拉非尼扩大准入计划的安全性和疗效结果。
Cancer. 2010 Mar 1;116(5):1272-80. doi: 10.1002/cncr.24864.
10
Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer.索拉非尼用于转移性乳腺癌患者的多中心非对照II期试验。
Anticancer Drugs. 2009 Aug;20(7):616-24.

引用本文的文献

1
Management of dermatologic adverse events from cancer therapies: recommendations of an expert panel.癌症治疗引起的皮肤不良反应管理：专家小组建议
An Bras Dermatol. 2020 Mar-Apr;95(2):221-237. doi: 10.1016/j.abd.2020.01.001. Epub 2020 Feb 15.
2
Selective use of sorafenib in the treatment of thyroid cancer.索拉非尼在甲状腺癌治疗中的选择性应用。
Drug Des Devel Ther. 2016 Mar 11;10:1119-31. doi: 10.2147/DDDT.S82972. eCollection 2016.
3
Treatment compliance and severe adverse events limit the use of tyrosine kinase inhibitors in refractory thyroid cancer.
治疗依从性和严重不良事件限制了酪氨酸激酶抑制剂在难治性甲状腺癌中的应用。
Onco Targets Ther. 2015 Sep 3;8:2435-42. doi: 10.2147/OTT.S86322. eCollection 2015.
4
Effects of Sorafenib Dose on Acquired Reversible Resistance and Toxicity in Hepatocellular Carcinoma.索拉非尼剂量对肝细胞癌获得性可逆性耐药及毒性的影响
Cancer Res. 2015 Jun 15;75(12):2510-9. doi: 10.1158/0008-5472.CAN-14-3687. Epub 2015 Apr 23.
5
Clinical experience and critical evaluation of the role of sorafenib in renal cell carcinoma.索拉非尼在肾细胞癌中作用的临床经验与批判性评估。
Open Access J Urol. 2011 May 10;3:69-82. doi: 10.2147/OAJU.S7230.
6
Feasibility study of intra-patient sorafenib dose-escalation or re-escalation in patients with previously treated advanced solid tumors.经治的晚期实体瘤患者中索拉非尼患者内剂量递增或再递增的可行性研究。
Invest New Drugs. 2012 Oct;30(5):2001-7. doi: 10.1007/s10637-011-9761-y. Epub 2011 Oct 21.
7
Enhancing the clinical activity of sorafenib through dose escalation: rationale and current experience.通过剂量升级提高索拉非尼的临床活性：原理和现有经验。
Ther Adv Med Oncol. 2011 Mar;3(2):95-100. doi: 10.1177/1758834010396117.